Novogene Co (SHSE:688315) Other Current Payables: ¥76 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688315 Novogene Co Ltd SHSE:688315
86 GF Score
Price ¥13.77
GF Value ¥16.03
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Novogene Co Other Current Payables?

Novogene Co SHSE:688315 +4.00% 86 Other Current Payables is ¥76 Mil as of Mar. 2026. GuruFocus rates SHSE:688315 with a GF Score™ of 86/100 and a GF Value™ of ¥16.03 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Novogene Co's Other Current Payables for the quarter that ended in Mar. 2026 was ¥76 Mil.

Novogene Co's quarterly Other Current Payables increased from Sep. 2025 (¥85 Mil) to Dec. 2025 (¥93 Mil) but then declined from Dec. 2025 (¥93 Mil) to Mar. 2026 (¥76 Mil).

Novogene Co's annual Other Current Payables increased from Dec. 2023 (¥76 Mil) to Dec. 2024 (¥89 Mil) and increased from Dec. 2024 (¥89 Mil) to Dec. 2025 (¥93 Mil).

Novogene Co Other Current Payables Related Terms

Novogene Co Other Current Payables Historical Data

* Premium members only.

The historical data trend for Novogene Co's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novogene Co Other Current Payables Chart

Novogene Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 76.80 71.32 76.37 89.49 92.71

Novogene Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 68.75 78.50 85.45 92.71 76.22
SHSE:688315
86GF Score
Novogene Co Ltd SHSE:688315
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novogene Co Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of ¥76 Mil mean?
Novogene Co (SHSE:688315) has a Other Current Payables of ¥76 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Novogene Co and its competitors.
Is Novogene Co's Other Current Payables too high?
Novogene Co's current Other Current Payables is ¥76 Mil. Overall, Novogene Co has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novogene Co's Other Current Payables compare to VRTX and REGN?
Novogene Co's Other Current Payables of ¥76 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Novogene Co and its competitors. Novogene Co's current Other Current Payables is ¥76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novogene Co stock overvalued right now?
Based on GuruFocus' analysis, Novogene Co (SHSE:688315) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥16.03, compared to a current price of ¥13.77 — trading 14.1% below its estimated fair value. The current Other Current Payables is ¥76 Mil. Novogene Co's overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Novogene Co (SHSE:688315), the current Other Current Payables is ¥76 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novogene Co (SHSE:688315) Overvalued in 2026?

Based on GuruFocus' analysis, Novogene Co stock appears to be undervalued. The current stock price of ¥13.77 is trading 14.1% below its estimated GF Value™ of ¥16.03. GuruFocus considers Novogene Co to be Modestly Undervalued.

Key valuation signals for SHSE:688315:

  • Other Current Payables: ¥76 Mil
  • GF Value™: ¥16.03 vs. price of ¥13.77 (14.1% below fair value)
  • GF Score™: 86/100 with 2 warning signs

No single metric tells the full story. See the SHSE:688315 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novogene Co Business Description

Address No. 29, Shengshengyuan Road, Room B258, Innovation Building, Huilongguan Town, Changping District, Beijing, CHN, 100015
Novogene Co Ltd is engaged in providing multi-level scientific research and technical services and solutions for life science basic research, medical and clinical application research, and independent development and innovation of genetic testing medical equipment.
86GF Score

Get the complete analysis for SHSE:688315

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥13.77
Price
¥16.03
GF Value